An Innovative Canadian Pharmaceutical Company
Revenue Projected at $160,000,000 by 2025
Chief Executive Officer & Vice-Chairman of the Board of Directors
Mr. Saviuk started his career in accounting at KPMG. He quickly moved to venture capital investing through Manitex Capital Inc., a TSXV-listed company he co-founded over 30 years ago, and which still actively invests in emerging companies with a focus on the life science, renewable energy and sustainable resource sectors. Mr. Saviuk is President and CEO of Manitex Capital inc.
Mr. Saviuk co-founded Valeo Pharma in 2003 and has since served as its President and CEO. Mr. Saviuk transformed Valeo Pharma from its early years as an in-licensor of established brands to a fast growing full service Canadian pharmaceutical company and was also instrumental in the sale of certain assets to Valeant Canada. In addition to Mr. Saviuk's executive management experience, he is well acquainted with key corporate governance issues having served on numerous boards of both public and private companies.
Mr. Saviuk hold a degree in Business (B.Comm) from Concordia University (Montreal, Qc).
President and Chief Operating Officer
Frederic Fasano is a seasoned pharma executive with over 25 years of experience in managing strategic affiliates within different geographies ( Canada , Europe , Latin America ). Prior to joining Valeo, Frederic served as President and CEO of Servier Canada, a well-established fully integrated affiliate of Servier Group. He led the portfolio diversification strategy, including multiple in-licensing deals, while strengthening the team capabilities in order to maximize the affiliate's growth. Mr. Fasano held various executive positions in Italy , France and Latin America and sat on the Board of Directors of ILKOS Therapeutics. He also served as Chairman of the Board of Innovative Medicines Canada. He holds a Master of Business Administration from ESSEC Business School ( France ) and a Pharm. Degree from Paris-XI School of Pharmacy ( France ).
Senior Vice-President and Chief Financial Officer
In addition to his position with Valeo Pharma, Mr. Mainville is currently the President of Luma Life and Senior Vice-President and Chief Financial Officer of Ortho Regenerative Technologies Inc. He, previously served as Interim Chief Executive Officer at Acerus Pharmaceuticals Corp., Executive Vice President at Cardiome Pharma Corp., President and Chief Executive Officer of Neopharm Labs Inc. and LAB Research Inc.
Mr. Mainville has gained considerable experience throughout his career in senior management roles, including chief financial officer positions for several private and public life science companies such as RTP Pharma, Waratah Pharma, URRMA Biopharma and LAB International. In particular, Mr. Mainville has led or been involved in four distinct IPOs/RTOs, completed more than 20 public financings, and led more than 50 licensing, sale, merger and acquisition transactions. He serves or served as a director for a number of public and private companies in the biotechnology and pharmaceutical industries as well as Chair of the Audit Committee for a number of boards, including that of Acerus Pharmaceuticals, AAA Medic, Enobia Pharma, Powertech Corporation, Cyplasin Biomedical and Chairman of the board of Zucara Therapeutics, Alethia BioTherapeutics and Bioaxone Theratpeutics. He served as Vice-Chairman of BIOTECanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, Mr. Mainville was a Partner at KPMG LLP.
Ms. Saviuk was Chief Financial Officer of the Corporation from January 2008 to September 2018. She was involved in setting the base structure for various departments of the company, specifically concentrating on all financial operations, as well as supply chain management. Previously, Ms. Saviuk has held various positions in financial accounting throughout her career and has been Chief Financial Officer of Manitex Capital Inc. since 2010.
Ms. Saviuk holds a degree in Business (B.Comm) from Concordia University (Montreal, Qc) and a Certificate in Accounting from Mc Gill University (Montreal, Qc).
Senior Vice-President, Chief Commercial Officer
Mr. Léger is a seasoned pharmaceutical executive with pan-Canadian and U.S. experience in both the prescription pharmaceutical and consumer healthcare businesses. He has extensive experience in building and leading organizations and has an excellent track record of developing best in class brands.
Mr. Léger began his career in the pharmaceutical industry in 1984 with Schering Canada as a sales representative in British Columbia. He progressed through the organization in a variety of roles in the marketing and sales departments (Canada and U.S.) leading to the role of Vice President, Primary Care Business Unit (1997-2002) and subsequently to the role of General Manager, Schering-Plough Healthcare Canada (2002-2008), where he led the Consumer Health Business. During his career at Schering-Plough, Mr. Léger was directly involved with the launch and/or development of over 15 brands which became leading brands in their respective markets, and managed and led several organizational structure changes.
In February 2009, Mr. Léger joined Valeo Pharma, leading the Commercial Operations where he was directly involved with the development of both the dermatology and specialty products businesses, which were in part sold to Valeant Pharmaceuticals Inc. (now Bausch Health) in 2014. Currently, as Senior VP and Chief Commercial Officer, Mr. Léger leads all of the commercial facets of the in-line products and is involved in the new business development initiatives.
Mr. Léger graduated from Concordia University (Montreal, Qc) in 1984 with a Bachelor of Arts degree (Economics).
Vice-President, Business Development
Mr. Skinner has worked in the Canadian Healthcare industry for 15 years, with a focus on Business Development and Licensing. His experience includes time at a clinical stage medical device company, the Canadian affiliate of an international pharmaceutical company, and several early stage biotech companies. Prior to joining Valeo Pharma in 2014, Mr. Skinner worked for SteriMax Inc., a Canadian generic pharmaceutical company. At Valeo Pharma, Mr. Skinner is responsible for all business development activities, including the identification and evaluation of new product opportunities, and the negotiation of contracts for product rights.
Mr. Skinner holds a Bachelor's degree in Science (BSc.) and a Master's Degree in Business Administration (MBA), both from the University of Western Ontario (London, Ont.).
VP of Quality Assurance and Regulatory Affairs
Ms. Therrien has worked in the pharmaceutical industry for over 20 years, with a focus on quality assurance and regulatory affairs of health products. She has a strong expertise in compliance with Health Canada, FDA, and EU regulations for health products including ISO 13485 certifications. Ms. Therrien joined Valeo Pharma in January 2016. Prior to joining the Corporation Ms. Therrien worked at A.R Medicom, a health care company that manufactures infection control products, from January 2012 to January 2016 as Corporate Director of Quality Assurance and Regulatory Affairs ensuring regulatory compliance of all manufacturing sites. Before joining A.R Medicom, Ms. Therrien worked at Anapharm Inc. (now Inventiv Health Clinique), a clinical research organization, for 5 years as a Director of Clinical operations and at Sanofi for over 14 years where she held different positions within the quality department. At Valeo Pharma, Ms. Therrien oversees and directs quality assurance and regulatory affairs activities to ensure regulatory compliance including pharmaceutical product approval activities.
Ms. Therrien holds a B.Sc. in Science from Université du Québec à Montréal.
Guy Paul Allard
Vice-President, Legal Affairs and Corporate Secretary
Mr. Allard is a lawyer and Member of the Quebec Bar since 1996. In addition to his position with Valeo Pharma, Mr. Allard is Vice-President, Legal Affairs and Corporate Secretary for Manitex Capital Inc. and Ortho Regenerative Technologies Inc., two affiliates of Valeo Pharma, since April 2016. From 2007 to 2016, he was Partner and Counsel at Dentons, a multinational law firm where he specialized in corporate finance, securities, and mergers and acquisitions. Throughout his career, he has been counsel to several publicly-listed companies on various matters.
Mr. Allard holds a Bachelor's degree in Business Administration (B.A.A), a Certificate in Law and a Bachelor's degree in Law (LL.B.) from Laval University (Quebec City).